Inotek Pharmaceuticals
Inotek Pharmaceuticals is a privately held, clinical-stage biotechnology company developing small-molecule ophthalmic drugs, led by trabodenoson, a selective adenosine A1 receptor agonist in late Phase 2 trials for open-angle glaucoma and ocular hypertension, with a PARP inhibitor preclinical program for retinal disease.
- Company typePrivate
- Founded2004
- HeadquartersLexington, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Inotek Pharmaceuticals does
Inotek Pharmaceuticals Corporation is a privately held, clinical-stage biotechnology company founded in the late 1990s and headquartered in Lexington, Massachusetts. It develops small-molecule drug candidates for serious diseases of the eye, with its lead program trabodenoson (INO-8875) — a highly selective adenosine A1 receptor agonist designed to lower intraocular pressure by augmenting the trabecular meshwork drainage pathway in patients with open-angle glaucoma and ocular hypertension. Trabodenoson has completed Phase 1 and Phase 2 trials and was advancing into a multiple-dose late Phase 2 study at the time of the disclosures. The pipeline also includes a trabodenoson plus latanoprost fixed-dose combination and a preclinical poly(ADP-ribose) polymerase (PARP) inhibitor program targeting age-related macular degeneration and diabetic retinopathy, addressing oxidative stress in retinal tissue.
The company's core technology is a proprietary adenosine mimetic chemistry platform built on rational structure-activity relationships for adenosine receptor sub-types, paired with PARP inhibitor research; selective A1 agonism is positioned as the key differentiator against existing glaucoma drugs such as prostaglandin analogues. Revenue mechanics are pre-commercial: the company has no approved product, monetizes through future pharma partnering or licensing, and has historically funded operations with over $50 million in non-dilutive federal and private grants (1997-2004) plus over $100 million in equity capital from life-sciences investors including Care Capital, Devon Park Bioventures, MedImmune Ventures, Pitango Venture Capital, Rho Ventures, and Horizon Technology Finance. A secondary consumer-facing online storefront reselling generic glaucoma eye drops (bimatoprost, latanoprost) appears on the corporate website alongside the biotech corporate materials; no revenue from this channel is disclosed and its strategic role is ambiguous.
The end users are patients with open-angle glaucoma, ocular hypertension, and retinal disease, reached indirectly through ophthalmologists and a future commercialization partner rather than a direct sales force. The customer concentration question is therefore not yet meaningful: there are no paying customers, and the company's clinical-stage model depends on partner-led commercialization rather than in-house selling. Management is led by President & CEO Paul G. Howes (formerly of Bausch & Lomb and Merck), with clinical leadership from EVP & CMO Rudolf A. Baumgartner, MD (former Sepracor VP with multiple NDA approvals), and scientific direction from CSO William K. McVicar and founding Principal Fellow Garry J. Southan, PhD.
Inotek Pharmaceuticals firmographics
Firmographics- Name
- Inotek Pharmaceuticals
- Legal name
- Inotek Pharmaceuticals Corporation
- Website
- https://inotekcorp.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Inotek Pharmaceuticals is a privately held, clinical-stage biotechnology company developing small-molecule ophthalmic drugs, led by trabodenoson, a selective adenosine A1 receptor agonist in late Phase 2 trials for open-angle glaucoma and ocular hypertension, with a PARP inhibitor preclinical program for retinal disease.
- Ownership category
- akta.pro rank
Inotek Pharmaceuticals industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where Inotek Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Lexington
- HQ country
- United States
- HQ region
- North America
Markets served
Inotek Pharmaceuticals business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Marketing channels1 record
Inotek Pharmaceuticals product offering
Product offeringCore offering
Inotek Pharmaceuticals is a privately held clinical-stage biotechnology company focused on the discovery and development of drug candidates targeting serious eye diseases. Its lead program, trabodenoson (INO-8875), is a highly selective adenosine A1 receptor agonist in Phase 2 clinical trials for the treatment of elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension. The company also develops PARP inhibitors for retinal diseases and operates an online pharmacy selling branded and generic ophthalmic medications.
Product overview
Inotek Pharmaceuticals is a privately held biotechnology company developing a pipeline of ophthalmic drug candidates. The core product is trabodenoson (INO-8875), a highly selective adenosine A1 receptor agonist in Phase 2 clinical trials for glaucoma treatment. The company also develops a fixed-dose combination of trabodenoson with latanoprost, and maintains a preclinical pipeline of PARP inhibitors for retinal diseases. Additionally, the company operates an online pharmacy platform selling branded and generic eye medications including Careprost, Lumigan, Bimatoprost, and Xalatan.
Differentiator
Problem solved
Functional benefit
Products and services
- Trabodenoson (INO-8875)
- Trabodenoson Fixed-Dose Combination (FDC)
- PARP Inhibitors (Preclinical Pipeline)
- Online Pharmacy Platform
Quantifiable outcome
- After 28 days of trabodenoson monotherapy, efficacy was in the range of market-leading prostaglandins such as latanoprost
- +3 more outcomes
Companies that use Inotek Pharmaceuticals
Customer profileSegments2 records
Ideal customer profiles3 records
Inotek Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Inotek Pharmaceuticals partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights3 records
Inotek Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Bausch + Lomb (Bausch Health): Major global ophthalmology company with a full portfolio including branded and generic glaucoma products. CEO Paul Howes previously led the Americas Region at Bausch & Lomb, and the company is a credible strategic acquirer of glaucoma assets like trabodenoson.
- Allergan (AbbVie): Marketer of Lumigan (bimatoprost) and a major incumbent in branded ophthalmology with strong physician relationships and global commercialization infrastructure. Sets the standard that trabodenoson would need to compete against in IOP-lowering.
- Pfizer: Original developer and historical marketer of Xalatan (latanoprost), the market-leading prostaglandin and benchmark for trabodenoson's Phase 2 efficacy comparison. Sets the dominant efficacy standard in the IOP-lowering category.
Direct peers
- Aerpio Pharmaceuticals: Clinical-stage ophthalmology biotech that developed novel therapies for glaucoma and other ocular diseases targeting the trabecular meshwork outflow pathway. Directly comparable as a small-cap glaucoma-focused specialty pharma.
- Iveric Bio (Astellas): Now part of Astellas, Iveric Bio developed therapeutics for retinal diseases including age-related macular degeneration. Directly comparable as an ophthalmology/retinal-disease biotech that progressed novel ocular drugs to commercialization.
- Aerie Pharmaceuticals: Aerie was a clinical-to-commercial ophthalmology specialty pharma focused on novel glaucoma therapies (Rhopressa/Roclanda) before being acquired by Alcon. Directly comparable as a small, glaucoma-focused specialty pharma developing novel-mechanism IOP-lowering agents.
- Nicox: European ophthalmology specialty company developing novel therapeutics for glaucoma and ocular surface diseases (including VYZULTA, a latanoprost-based FDC). Directly comparable as a smaller, product-focused glaucoma company with similar strategic positioning.
- Kala Pharmaceuticals: Clinical-stage ophthalmology specialty pharma that developed novel formulations for ocular surface and retinal diseases. Comparable as a similarly-sized ophthalmology-focused drug developer pursuing specialty indications.
- Ocular Therapeutix: Ophthalmology specialty company developing sustained-release drug delivery and clinical-stage ocular therapeutics. Comparable as a similarly-sized clinical-stage ophthalmic drug developer with a comparable product-stage profile.
Emerging players
- Regenxbio: Clinical-to-commercial gene therapy company with a meaningful ophthalmology franchise targeting retinal diseases (wet AMD, diabetic retinopathy). Adjacent comparable as a competitor to Inotek's PARP inhibitor preclinical program in retinal indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights7 records
Customer concentration
Inotek Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inotek Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles6 records
Inotek Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds6 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inotek Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inotek Pharmaceuticals
What does Inotek Pharmaceuticals do?
Inotek Pharmaceuticals is a privately held clinical-stage biotechnology company focused on the discovery and development of drug candidates targeting serious eye diseases. Its lead program, trabodenoson (INO-8875), is a highly selective adenosine A1 receptor agonist in Phase 2 clinical trials for the treatment of elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension. The company also develops PARP inhibitors for retinal diseases and operates an online pharmacy selling branded and generic ophthalmic medications.
Is Inotek Pharmaceuticals a public or private company?
Inotek Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Inotek Pharmaceuticals founded?
Inotek Pharmaceuticals was founded in 2004. It employs 11 to 50 people.
Where is Inotek Pharmaceuticals based?
Inotek Pharmaceuticals is headquartered in Lexington, United States, in the North America region.
Who are Inotek Pharmaceuticals's main competitors?
Broad incumbents on record are Bausch + Lomb (Bausch Health), Allergan (AbbVie) and Pfizer. Direct peers are Aerpio Pharmaceuticals, Iveric Bio (Astellas), Aerie Pharmaceuticals, Nicox, Kala Pharmaceuticals and Ocular Therapeutix. Regenxbio is listed as an emerging player.
Does Inotek Pharmaceuticals have an API?
No public API is recorded for Inotek Pharmaceuticals.
What industry is Inotek Pharmaceuticals in?
Inotek Pharmaceuticals's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.